Archive
-
2021/11/01Breakthrough! Furmonertinib achieves positive results from the study on the first-line treatment of advanced NSCLC.
-
2021/10/31Good news in October: Furmonertinib has quickly covered 10 cities.
-
2021/10/29Accelerated Breakthrough: Allist’s Q3 financial report. Performance overview:
-
2021/09/22Allist Chief Chemistry Officer Dr. Luo Huibing: “Precision R&D” with Artistic Elegance
-
2021/09/18Data from Furmonertinib studies for EGFR 20 exon insertion mutations presented at ESMO Congress 2021
-
2021/09/02Dongguan Citizen Insurance Upgraded: Care-free Furmonertinib
-
2021/09/01Furmonertinib Entered Wuxi: Inclusive Commercial Insurance List Upgraded
-
2021/09/01Lecheng, Boao rolls out global special drug insurance 2021 where Furmonertinib incorporated!
-
2021/08/24Allist 2021 Semi-annual Report
-
2021/08/24Allist awarded “Emerging Medical Innovator in China 2021” by PHIIC